Lallemand inaugurates its newest division - Lallemand Health Solutions
Montreal, Canada... Lallemand Inc is pleased to announce the birth of its new division Lallemand Health Solutions.
Montreal, Canada... Lallemand Inc is pleased to announce the birth of its new division ‘’Lallemand Health Solutions’’. This new entity consolidates the internationally recognized probiotic manufacturers Institut Rosell and Harmonium International. Collectively they possess close to a century of probiotic expertise in the selection, development, production and marketing of probiotic strains, and formulations that support human health and well-being.
Lallemand Health Solutions will be dedicated in bringing to its customers, which span from the food supplement to the pharmaceutical industries, the highest quality probiotic solutions produced within current GMP and ISO 9001 environments. Thanks to its fully integrated offer ‘’Lallemand Health Solutions’’ is a unique probiotic player in the global arena that can provide its customers and partners solutions from fermentation and lyophilization all the way to finished product capabilities; a true one stop shop probiotic solutions provider.
The new division, headquartered in Montreal, Canada, is managed by Mrs. Francine Mondou, former co-founder and president of Harmonium International and is covering more than 30 countries across 5 continents ready to service your probiotic needs.
‘’Lallemand Health Solutions’’ recognized also as ‘’LHS’’, offers a full line of ready-to-market probiotic formula’s such as ; LACIDOFIL®, PROBIO’KID®, PRIOBIO’STICK®, PROTECFLOR® , can also design, develop and produce custom formulations based on the documented ROSELL®, LAFTI® or HARMONIUM® strains. Such formulations can also include premium vitamin and mineral yeasts or β-Glucans, developed and produced by the Lallemand group under the LALMIN® brand. All formulations can be delivered in bulk powder or finished product formats such as: capsules, tablets, sachets, sticks, and bottles.
Available ready-to-market probiotic blends targeting specific health segments:
• Gastrointestinal health: IBS, AAD, travelers diarrhea, …
• Immunity: kids and adults
• Women healthcare: UTI, Candidiasis, …
• Stress and anxiety
From the lab to shelf, ‘’Lallemand Health Solutions’’ controls the overall manufacturing process of its products. Our probiotic strains and formulas are produced in-house in one of our many bacteria and yeast production facilities available at the Lallemand Group to ensure customers are receiving the highest quality standard of probiotic formulations.
Institut Rosell Inc. was founded by microbiologists Dr Rosell and Dr Edouard Brochu in 1934 in Montreal and stands as a pioneer of probiotics development in North America. The Institut was acquired by the Lallemand group in 1998. Since then, with intensive research programs and a solid international partnership network with renowned research institutes, hospitals and universities, the company has always pursued its founder’s mission to document and demonstrate the benefits of probiotics on health and well-being.
Harmonium International Inc. was created in 1998 in Montreal and incorporated into Lallemand in 2011. Harmonium International's mission remains simple to this day; apply our know-how into producing unmatched quality probiotic micro-organisms, add a good portion of great customer service, personally educate and train our business partners on the health benefits of good bacteria, and formulate the best probiotic complexes to meet our clients’ needs. These longstanding ingredients have become the formula for Harmonium’s success, credibility and a reference to high quality probiotics.
Related News
-
News Understanding the Benefits and Advances of Cleanroom Technology
In an industry where precision and sterility are crucial concerns, cleanrooms play a vital role in maintaining the integrity of pharmaceutical products like drugs, vaccines, and other medical products. So, what is a cleanroom?
-
News AbbVie secures GBP£1.2 billion deal for Gilgamesh’s psychedelic programme
AbbVie has penned a significant agreement to acquire the bretisilocin programme from Gilgamesh Pharmaceuticals for up to £1.2 billion, marking a bold step in the pharmaceutical giant's quest to develop treatments for psychiatric disorders. -
News Gates Foundation commits US$2.5 billion to women’s health research
The Bill & Melinda Gates Foundation has announced a substantial US$2.5 billion commitment to accelerate research and development focused exclusively on women's health through 2030.
-
News Mid-year review: notable FDA drug approvals of 2025
As we fly past the halfway point of 2025, the pharmaceutical landscape reliably continues to evolve with innovative therapies addressing critical medical needs. The FDA has already approved 17 groundbreaking medications this year, each representin... -
News US FDA announces new priority vouchers for accelerated review times
The US FDA announced a new priority program for drug developers – the Commissioner’s National Priority Voucher (CNPV) program aims to enhance the health interests of the US by allowing drug developers to redeem a voucher, shortening th... -
News Google-backed start-up raises US$600 million to support AI drug discovery and design
London-based Isomorphic Labs, an AI-driven drug design and development start-up backed by Google’s AI research lab DeepMind, has raised US$600 million in its first external funding round by Thrive Capital. The funding will provide further power t... -
News AstraZeneca to invest US$2.5 billion in Beijing R&D centre
Amid investigations of former AstraZeneca China head Leon Wang in 2024, AstraZeneca have outlined plans to establish its sixth global strategic R&D centre in China. Their aim is to further advance life sciences in China with major research and manufact... -
News Experimental drug for managing aortic valve stenosis shows promise
The new small molecule drug ataciguat is garnering attention for its potential to manage aortic valve stenosis, which may prevent the need for surgery and significantly improve patient experience.